enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Meet the Biotech Stock That Has Generated Nvidia-Like ... - AOL

   www.aol.com/finance/meet-biotech-stock-generated...

   That stock is Bright Minds Biosciences (NASDAQ: DRUG) This stock had a market cap of less than $5 million a month ago. ... Each day last week, its trading volume was above 300,000.

3. Bright Minds' Second-Gen Psychedelic Drugs Ready to Be ... - AOL

   www.aol.com/news/bright-minds-second-gen...

   Bright Minds Biosciences (OTC: BMBIF), a Canadian-based biotechnology company, is developing the next-generation serotonergic drugs to treat various central nervous system (CNS) disorders. Over ...

4. Bright Minds Biosciences and Firefly Neuroscience to ...

   lite.aol.com/tech/story/0022/20241021/9258929.htm

   NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial ...

5. BMB-201 - Wikipedia

   en.wikipedia.org/wiki/BMB-201

   BMB-201 is under development by Bright Minds Biosciences. [ 1 ] [ 2 ] As of October 2024, its highest developmental phase is preclinical research . [ 1 ] [ 2 ] The chemical structure of BMB-201 does not yet appear to have been disclosed.

6. These are the 6 most important stock market charts technical ...

   www.aol.com/6-most-important-stock-market...

   Wall Street experts highlighted the most important stock market charts to watch into next year. From interest rates to software stocks, here's what Wall Street's top technical experts are watching ...

7. BMB-202 - Wikipedia

   en.wikipedia.org/wiki/BMB-202

   BMB-202 is under development by Bright Minds Biosciences. [ 1 ] [ 2 ] As of April 2023, it is in preclinical research for depressive disorders and PTSD. [ 1 ] [ 2 ] The chemical structure of BMB-202 does not yet appear to have been disclosed, [ 1 ] [ 2 ] but it seems that it may be a phenethylamine . [ 5 ]

8. 3 Russell 2000 Growth Stocks That Could Be Worth the Risk - AOL

   www.aol.com/3-russell-2000-growth-stocks...

   Speaking to this point, Wall Street's consensus price target on Avidity Biosciences' stock suggests a 36.4% upside in the next 12 months. However, investors should remember that the company's ...

9. BMB-101 - Wikipedia

   en.wikipedia.org/wiki/BMB-101

   BMB-101 is under development by Bright Minds Biosciences. [ 1 ] [ 2 ] As of October 2023, it is in phase 2 clinical trials for absence epilepsy and Pitt-Hopkins syndrome, phase 1 clinical trials for Dravet syndrome, and is in preclinical research for binge-eating disorder, Lennox-Gastaut syndrome, and opioid-related disorders.